Mendelian randomization analysis using genetic variants affecting GLP1R expression found that GLP-1 receptor agonists reduce paralytic ileus risk by 77% (OR = 0.23), with less than 3% of this protective effect mediated through blood sugar or weight changes. The study examined 24 gastrointestinal disorders and found no causal links to other GI complications like pancreatitis or gallstones. This genetic evidence challenges observational studies that have suggested broader GI risks with these diabetes medications. The finding carries significant clinical weight because paralytic ileus—where intestinal muscles fail to contract properly—can be a serious postoperative complication requiring emergency intervention. For the millions using GLP-1 agonists like semaglutide and liraglutide, this represents an unexpected protective benefit operating through mechanisms largely independent of their known metabolic effects. The Mendelian randomization approach strengthens causal inference by using genetic variants as natural experiments, avoiding confounding factors that plague observational research. However, the protective mechanism remains unclear, and the finding requires validation in clinical trials. This represents confirmatory evidence that GLP-1 drugs' effects extend beyond glucose control, while simultaneously providing reassurance about their gastrointestinal safety profile.